RHÖN-KLINIKUM H1 Profit Declines; Confirms 2025 Outlook

RHÖN-KLINIKUM reported a mixed first half, with consolidated profit decreasing to €14.7 million from €20.6 million, and EBITDA falling to €46.7 million from €49.1 million, alongside a drop in EPS to €0.21. This profitability decline occurred despite a 7.5% increase in revenues to €883.5 million and a 1.8% rise in patient volume. For the current fiscal year, the company projects revenues of €1.7 billion (±5%) and EBITDA between €110 million and €125 million.

Analysis

RHÖN-KLINIKUM's first-half results present a clear case of revenue growth failing to translate into profitability. While revenues increased a robust 7.5% to 883.5 million euros, driven by a 1.8% rise in patient volume, this top-line strength was overshadowed by significant margin compression. EBITDA declined to 46.7 million euros from 49.1 million euros year-over-year, and consolidated profit fell sharply to 14.7 million euros from 20.6 million euros, causing earnings per share to drop to 0.21 euros. This divergence indicates rising operational costs are eroding earnings. The company's full-year guidance appears optimistic, projecting revenues of 1.7 billion euros (±5%) and an EBITDA between 110 million and 125 million euros. Achieving this EBITDA target necessitates a substantial profitability improvement in the second half, as the company must generate at least 63.3 million euros in H2 EBITDA, a marked acceleration from the 46.7 million euros delivered in H1.

Key Decisions for Investors

• Investors should scrutinize upcoming quarterly reports for evidence of margin recovery, as the current trajectory places significant execution risk on the company's ability to meet its full-year EBITDA guidance.
• Given the disconnect between revenue growth and profitability, it is crucial to assess whether the 7.5% revenue increase is sustainable and if management can implement effective cost controls in the second half.
• A neutral or hold position may be prudent until there are clear signs that the profitability decline has bottomed out and the significant second-half operational improvement implied by the guidance begins to materialize.